Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Mesothelioma
Closed
Phase 1/2
This trial is looking at a drug called ganetespib alongside standard chemotherapy for mesothelioma in the covering of the lungs (the pleura). The trial is supported by Cancer Research UK.
Mesothelioma is a type of cancer that can develop in the tissues covering the lungs or lining the abdomen. Mesothelioma affecting the lungs is called pleural mesothelioma.
Doctors can treat mesothelioma with chemotherapy. The chemotherapy drugs they normally use are pemetrexed and cisplatin or carboplatin.
In this trial, researchers want to see if they can improve the treatment of pleural mesothelioma by adding a drug called ganetespib.
Ganetespib is a type of biological therapy called a heat shock protein 90 inhibitor. It stops signals that cancer cells use to divide and grow.
The aims of this trial are to
Find the best dose of ganetespib to give alongside pemetrexed and cisplatin or carboplatin
See how well this combination of drugs works as treatment for pleural mesothelioma
Recruitment start: 21 August 2013
Recruitment end: 30 November 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Dean Fennell
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Synta Pharmaceuticals
University College London (UCL)
This is Cancer Research UK trial number CRUKE/09/025.
We have more information about the work of Prof Dean Fennell.
Last reviewed: 13 Jan 2016
CRUK internal database number: 4270
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
